AIMS: Tobacco dependence treatments achieve abstinence rates of 25-30% at 1 year. Low rates may reflect failure to conceptualize tobacco dependence as a chronic disorder. The aims of the present study were to determine the efficacy of extended cognitive behavioral and pharmacological interventions in smokers > or = 50 years of age, and to determine if gender differences in efficacy existed. DESIGN: Open randomized clinical trial. SETTING: A free-standing, smoking treatment research clinic. PARTICIPANTS: A total of 402 smokers of > or = 10 cigarettes per day, all 50 years of age or older. INTERVENTION: Participants completed a 12-week treatment that included group counseling, nicotine replacement therapy (NRT) and bupropion. Participants, independent of smoking status, were then assigned randomly to follow-up conditions: (i) standard treatment (ST; no further treatment); (ii) extended NRT (E-NRT; 40 weeks of nicotine gum availability); (iii) extended cognitive behavioral therapy (E-CBT; 11 cognitive behavioral sessions over a 40-week period); or (iv) E-CBT plus E-NRT (E-combined; 11 cognitive behavioral sessions plus 40 weeks nicotine gum availability). MEASUREMENTS: Primary outcome variable was 7-day point prevalence cigarette abstinence verified biochemically at weeks 24, 52, 64 and 104. FINDINGS: The most clinically important findings were significant main effects for treatment condition, time and the treatment x time interaction. The E-CBT condition produced high cigarette abstinence rates that were maintained throughout the 2-year study period [(week 24 (58%), 52 (55%), 64 (55%) and 104 (55%)], and was significantly more effective than E-NRT and ST across that period. No other treatment condition was significantly different to ST. No effects for gender were found. CONCLUSIONS: Extended cognitive behavioral treatments can produce high and stable cigarette abstinence rates for both men and women. NRT does not add to the efficacy of extended CBT, and may hamper its efficacy. Research is needed to determine if these results can be replicated in a sample with a greater range of ages, and improved upon with the addition of medications other than NRT.
RCT Entities:
AIMS: Tobacco dependence treatments achieve abstinence rates of 25-30% at 1 year. Low rates may reflect failure to conceptualize tobacco dependence as a chronic disorder. The aims of the present study were to determine the efficacy of extended cognitive behavioral and pharmacological interventions in smokers > or = 50 years of age, and to determine if gender differences in efficacy existed. DESIGN: Open randomized clinical trial. SETTING: A free-standing, smoking treatment research clinic. PARTICIPANTS: A total of 402 smokers of > or = 10 cigarettes per day, all 50 years of age or older. INTERVENTION: Participants completed a 12-week treatment that included group counseling, nicotine replacement therapy (NRT) and bupropion. Participants, independent of smoking status, were then assigned randomly to follow-up conditions: (i) standard treatment (ST; no further treatment); (ii) extended NRT (E-NRT; 40 weeks of nicotine gum availability); (iii) extended cognitive behavioral therapy (E-CBT; 11 cognitive behavioral sessions over a 40-week period); or (iv) E-CBT plus E-NRT (E-combined; 11 cognitive behavioral sessions plus 40 weeks nicotine gum availability). MEASUREMENTS: Primary outcome variable was 7-day point prevalence cigarette abstinence verified biochemically at weeks 24, 52, 64 and 104. FINDINGS: The most clinically important findings were significant main effects for treatment condition, time and the treatment x time interaction. The E-CBT condition produced high cigarette abstinence rates that were maintained throughout the 2-year study period [(week 24 (58%), 52 (55%), 64 (55%) and 104 (55%)], and was significantly more effective than E-NRT and ST across that period. No other treatment condition was significantly different to ST. No effects for gender were found. CONCLUSIONS: Extended cognitive behavioral treatments can produce high and stable cigarette abstinence rates for both men and women. NRT does not add to the efficacy of extended CBT, and may hamper its efficacy. Research is needed to determine if these results can be replicated in a sample with a greater range of ages, and improved upon with the addition of medications other than NRT.
Authors: D G Altman; K F Schulz; D Moher; M Egger; F Davidoff; D Elbourne; P C Gøtzsche; T Lang Journal: Ann Intern Med Date: 2001-04-17 Impact factor: 25.391
Authors: M Babyak; J A Blumenthal; S Herman; P Khatri; M Doraiswamy; K Moore; W E Craighead; T T Baldewicz; K R Krishnan Journal: Psychosom Med Date: 2000 Sep-Oct Impact factor: 4.312
Authors: J A Blumenthal; M A Babyak; K A Moore; W E Craighead; S Herman; P Khatri; R Waugh; M A Napolitano; L M Forman; M Appelbaum; P M Doraiswamy; K R Krishnan Journal: Arch Intern Med Date: 1999-10-25
Authors: J T Hays; R D Hurt; N A Rigotti; R Niaura; D Gonzales; M J Durcan; D P Sachs; T D Wolter; A S Buist; J A Johnston; J D White Journal: Ann Intern Med Date: 2001-09-18 Impact factor: 25.391
Authors: Richard D Hurt; James E Krook; Ivana T Croghan; Charles L Loprinzi; Jeff A Sloan; Paul J Novotny; Carl G Kardinal; James A Knost; Maria Tria Tirona; Ferdinand Addo; Roscoe F Morton; John C Michalak; Paul L Schaefer; Patricia A Porter; Philip J Stella Journal: J Clin Oncol Date: 2003-03-01 Impact factor: 44.544
Authors: Lisa Sanderson Cox; Christi A Patten; Raymond S Niaura; Paul A Decker; Nancy Rigotti; David P L Sachs; A Sonia Buist; Richard D Hurt Journal: J Gen Intern Med Date: 2004-08 Impact factor: 5.128
Authors: Timothy B Baker; Robin Mermelstein; Linda M Collins; Megan E Piper; Douglas E Jorenby; Stevens S Smith; Bruce A Christiansen; Tanya R Schlam; Jessica W Cook; Michael C Fiore Journal: Ann Behav Med Date: 2011-04
Authors: Richard A Brown; Kathleen M Palm Reed; Erika Litvin Bloom; Haruka Minami; David R Strong; Carl W Lejuez; Christopher W Kahler; Michael J Zvolensky; Elizabeth V Gifford; Steven C Hayes Journal: Nicotine Tob Res Date: 2013-07-24 Impact factor: 4.244
Authors: Timothy P Carmody; Kevin Delucchi; Carol L Duncan; Peter Banys; Joel A Simon; Sharon N Solkowitz; Joy Huggins; Sharon K Lee; Sharon M Hall Journal: Drug Alcohol Depend Date: 2011-10-19 Impact factor: 4.492
Authors: William G Shadel; Marc N Elliott; Ann C Haas; Amelia M Haviland; Nate Orr; Melissa M Farmer; Sai Ma; Robert Weech-Maldonado; Donna O Farley; Paul D Cleary Journal: Prev Med Date: 2014-12-04 Impact factor: 4.018
Authors: Andrew W Bergen; Harold S Javitz; Ruth Krasnow; Denise Nishita; Martha Michel; David V Conti; Jinghua Liu; Won Lee; Christopher K Edlund; Sharon Hall; Pui-Yan Kwok; Neal L Benowitz; Timothy B Baker; Rachel F Tyndale; Caryn Lerman; Gary E Swan Journal: Pharmacogenet Genomics Date: 2013-02 Impact factor: 2.089